Thymalin
No single human route established in this referenceHuman study reference
Research reference
Human study
Thymalin/epithalamin older-adult report
Repeated courses of tissue extracts; a complete reproducible amount/route schedule is not established by the abstract
6–8 years of observation; initial exposure over 2–3 years, with a separate annual-course group
Khavinson and Morozov, Neuroendocrinology Letters (2003) ↗When results may show
- When change was measured
- The report examined broad health/mortality outcomes. Limited methods and co-interventions prevent a reliable personal lifespan or onset prediction.
- When to assess
- 6–8 years of observation; initial exposure over 2–3 years, with a separate annual-course group
- Conditions and limitations
- 266 older adults in a long-term controlled report. Do not copy an annual mg cycle from secondary sites or equate thymalin extract with synthetic thymulin, thymogen or thymosin alpha-1.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Khavinson and Morozov, Neuroendocrinology Letters (2003)Do not copy an annual mg cycle from secondary sites or equate thymalin extract with synthetic thymulin, thymogen or thymosin alpha-1.